New trial aims to evaluate chemotherapy benefit for ER+/HER2- breast cancer patients

[News]

The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk early-stage estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer by reducing the risk of recurrence.

More... (https://www.news-medical.net/news/20260924/New-trial-aims-to-evaluate-chemotherapy-benefit-for-ER2bHER2-breast-cancer-patients.aspx)